Skip to main content
SpringerLink
Log in

ESMO 2022 personal non-small lung cancer (NSCLC) highlights

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

In this article, we summarize our personal non-small cell lung cancer (NSCLC) highlights from the ESMO 2022 meeting, covering developments in early- and advanced-stage NSCLC. In early-stage disease, many studies underlined possibilities of neoadjuvant and adjuvant treatment, including neoadjuvant immunotherapy combination strategies (INCREASE trial) or adjuvant targeted therapy with osimertinib in epidermal growth factor receptor (EGFR)-mutated NSCLC (updated results of ADAURA), both promoting interesting concepts to further improve outcomes in early-stage NSCLC. In late-stage disease, results from CodeBreak200, the first randomized phase III trial investigating the selective KRAS-G12C inhibitor sotorasib, define this agent as the new standard-of-care in a molecular-defined patient population after progression on platinum-doublet and immunotherapy. The IPSOS study supports atezolizumab as preferred first-line therapy in unfit older patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. n Engl J Med. 2022;386(21):1973–85. https://doi.org/10.1056/NEJMoa2202170.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Dickhoff C, Senan S, Schneiders FL, et al. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0‑1 non-small cell lung cancer: the INCREASE trial. BMC Cancer. 2020;20(1):764. https://doi.org/10.1186/s12885-020-07263-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Bahce I, Dickhoff C, Schneiders FL, et al. 950O Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable lung cancer: The INCREASE trial. Ann Oncol. 2022;33:S982. https://doi.org/10.1016/j.annonc.2022.07.1076.

    Article  Google Scholar 

  4. Herbst RS, Tsuboi M, John T, et al. Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. J Clin Oncol. 2020;38(18_suppl):LBA5. https://doi.org/10.1200/JCO.2020.38.18_suppl.LBA5.

    Article  Google Scholar 

  5. Tsuboi M, Wu YL, Grohe C, et al. LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA. Ann Oncol. 2022;33:S1413–S4. https://doi.org/10.1016/j.annonc.2022.08.047.

    Article  Google Scholar 

  6. Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with. N Engl J Med. 2021;384(25):2371–81. https://doi.org/10.1056/NEJMoa2103695.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Johnson ML, de Langen AJ, Waterhouse DM, et al. LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study. Ann Oncol. 2022;33:S1417–S8. https://doi.org/10.1016/j.annonc.2022.08.051.

    Article  Google Scholar 

  8. Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383(14):1328–39. https://doi.org/10.1056/NEJMoa1917346.

    Article  CAS  PubMed  Google Scholar 

  9. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. https://doi.org/10.1056/NEJMoa1606774.

    Article  CAS  PubMed  Google Scholar 

  10. Lee SM, Schulz C, Prabhash K, et al. LBA11 IPSOS: results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen. Ann Oncol. 2022;33:S1418–S9. https://doi.org/10.1016/j.annonc.2022.08.052.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine V/Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria, 6020

    Lena Horvath

  2. Department of Internal Medicine 2/Hematology and Oncology, Kardinal Schwarzenberg Klinikum GmbH, Schwarzach im Pongau, 5620, Austria

    Georg Pall

Authors
  1. Lena Horvath
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Georg Pall
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Georg Pall.

Ethics declarations

Conflict of interest

L. Horvath has no conflicts of interest to declare. G. Pall has is advisory board member and has received speakers honoraria from Roche, Amgen, BMS, and Astra-Zeneca.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Horvath, L., Pall, G. ESMO 2022 personal non-small lung cancer (NSCLC) highlights. memo 16, 97–99 (2023). https://doi.org/10.1007/s12254-023-00887-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-023-00887-0

Keywords

Search

Navigation